<DOC>
	<DOCNO>NCT00248495</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium cisplatin work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give surgery may kill tumor cell . PURPOSE : This phase II trial study well give pemetrexed disodium cisplatin surgery work treat patient stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Disodium Cisplatin Treating Patients Who Are Undergoing Surgery Stage I , Stage II , Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathologic complete response patient stage IB-IIIB non-small cell lung cancer treat neoadjuvant chemotherapy comprise pemetrexed disodium cisplatin follow surgery adjuvant pemetrexed disodium cisplatin . Secondary - Determine adverse event regimen patient . - Determine overall disease-free survival patient treat regimen . - Correlate response presence absence ERCC1 DHFR , thymidylate synthase , DPD , GARFT patient treat regimen . - Correlate fragile site chromosome 12 within SMRT gene metastasis definitive treatment regimen patient . OUTLINE : - Neoadjuvant chemotherapy : Patients receive pemetrexed disodium IV 10 minute follow cisplatin IV approximately 1 hour day 1 . Treatment repeat every 21 day 3 course . Patients evaluated disease resectability . Patients evidence disease progression proceed thoracotomy within next 28-48 day . - Thoracotomy : Patients find unresectable disease thoracotomy receive treatment study . Patients resectable disease undergo complete surgical resection tumor . Forty eighty day later , patient proceed adjuvant chemotherapy . - Adjuvant chemotherapy : Patients receive pemetrexed disodium cisplatin 2 course . Patients progressive disease completion neoadjuvant chemotherapy follow every 6 month . All patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 38 patient accrue study 6.5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Microscopically confirm nonsmall cell lung cancer Stage IB ( T2 , N0 , M0 ) , IIA ( T1 , N1 , M0 ) , IIB ( T2 , N1 , M0 T3 , N0 , M0 ) , IIIA ( T13 , N12 , M0 ) disease Satellite lesions one lobe ( T4 ) ( stage IIIB ) allow Meets 1 follow criterion : Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 10 mm long diameter Evaluable disease , define lesion chest CT scan measurable ( e.g. , illdefined mass mediastinal hilar adenopathy ) No metastatic disease except peribronchial/hilar lymph node ( N1 ) ipsilateral/subcarinal mediastinal lymph node ( N2 ) No N3 lymph node ( e.g. , contralateral mediastinal/hilar supraclavicular/scalene ) CT scan positron emission tomography ( PET ) scan AND mediastinoscopy No T4 primary tumor ( e.g. , mediastinal invasion ) No malignant pleural effusion Nonmalignant effusion ( i.e. , negative cytology , nonbloody , transudate ) allow Effusions visible CT scan large enough safe thoracentesis allow No exudative effusion , define 1 follow criterion : Pleural fluid protein : serum protein ratio &gt; 0.5 Pleural fluid lactic dehydrogenase ( LDH ) : serum LDH ratio ≥ 0.6 Pleural fluid LDH &gt; 200 IU/L No 1 area fludeoxyglucose ( FDG ) uptake outside area primary lung tumor OR evidence malignant pleural disease evidence pleural nodule PET scan Single area FDG uptake evaluate ( e.g. , biopsy ) metastatic disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic Bilirubin ≤ 1.5 mg/dL SGOT SGPT ≤ 1.5 time upper limit normal Renal Creatinine clearance ≥ 45 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No active malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy lung cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy lung cancer Surgery No prior surgery lung cancer At least 12 week since prior major surgery chest abdomen Other No concurrent aspirin nonsteroidal antiinflammatory drug ≥ 2 day ( 5 day drug long halflife [ e.g. , naproxen , piraoxicam , difunisal , nabumetone , rofecoxib , celecoxib ] 8 day long act agent ) , , 2 day completion pemetrexed disodium administration No concurrent participation another study involve chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
</DOC>